Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.